

FORM PTO-1390 (REV. 9-2001)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER 800.1015	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 10/088160	
INTERNATIONAL APPLICATION NO. PCT/IL00/00562		INTERNATIONAL FILING DATE September 13, 2000		PRIORITY DATE CLAIMED September 14, 1999	
TITLE OF INVENTION PHOSPHOLIPID PRODRUGS OF ANTI-PROLIFERATIVE DRUGS					
APPLICANT(S) FOR DO/EO/US Alexander KOZAK, et al.					
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:					
1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.					
2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.					
3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.					
4. <input checked="" type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (Article 31).					
5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))					
a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau).					
b. <input checked="" type="checkbox"/> has been communicated by the International Bureau.					
c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).					
6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).					
a. <input type="checkbox"/> is attached hereto.					
b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4).					
7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))					
a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau).					
b. <input type="checkbox"/> have been communicated by the International Bureau.					
c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.					
d. <input checked="" type="checkbox"/> have not been made and will not be made.					
8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).					
9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).					
10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).					
Items 11 to 20 below concern document(s) or information included:					
11. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.					
12. <input checked="" type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.					
13. <input checked="" type="checkbox"/> A FIRST preliminary amendment.					
14. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.					
15. <input type="checkbox"/> A substitute specification.					
16. <input type="checkbox"/> A change of power of attorney and/or address letter.					
17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.					
18. <input checked="" type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4).					
19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).					
20. <input checked="" type="checkbox"/> Other items or information: Copy of PCT International Search Report; Copy of PCT Request; Copy of Notification of Receipt of Demand (Form PCT/IPEA/402); Copies of References Cited; Letter re Priority; Certificate of Mailing by Express Mail					

U.S. APPLICATION NO. (if known) 37 CFR 1.51
10/088169

INTERNATIONAL APPLICATION NO.
PCT/IL00/00562

ATTORNEY'S DOCKET NUMBER
800.1015

21. ☒ The following fees are submitted:

BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):

Neither international preliminary examination fee (37 CFR 1.482)
nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO
and International Search Report not prepared by the EPO or JPO \$1040.00

International preliminary examination fee (37 CFR 1.482) not paid to
USPTO but International Search Report prepared by the EPO or JPO \$890.00

International preliminary examination fee (37 CFR 1.482) not paid to USPTO
but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$740.00

International preliminary examination fee (37 CFR 1.482) paid to USPTO
but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$710.00

International preliminary examination fee (37 CFR 1.482) paid to USPTO
and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00

ENTER APPROPRIATE BASIC FEE AMOUNT =

CALCULATIONS PTO USE ONLY

\$ 710

Surcharge of \$130.00 for furnishing the oath or declaration later than ☐ 20 ☐ 30
months from the earliest claimed priority date (37 CFR 1.492(e)).

\$

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$
Total claims	29 - 20 =		x \$18.00	\$ 162
Independent claims	1 - 3 =		x \$84.00	\$
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$280.00	\$

TOTAL OF ABOVE CALCULATIONS =

\$ 872

☒ Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above
are reduced by 1/2.

\$

SUBTOTAL =

\$ 436

Processing fee of \$130.00 for furnishing the English translation later than ☐ 20 ☐ 30
months from the earliest claimed priority date (37 CFR 1.492(f)).

\$

TOTAL NATIONAL FEE =

\$ 436

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be
accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +

\$

TOTAL FEES ENCLOSED =

\$ 436

Amount to be
refunded:

\$

charged:

\$

a. ☒ A check in the amount of \$ 526.00 to cover the above fees is enclosed.

b. ☐ Please charge my Deposit Account No. 50-0552 in the amount of \$ to cover the above fees.
A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any
overpayment to Deposit Account No. 50-0552. A duplicate copy of this sheet is enclosed.

d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. **Credit card
information should not be included on this form.** Provide credit card information and authorization on PTO-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR
1.137 (a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

DAVIDSON, DAVIDSON & KAPPEL, LLC

485 Seventh Avenue, 14th Floor

New York, NY 10018

U.S.A.

Telephone No. (212) 736-1940

Facsimile (212) 736-2427

SIGNATURE

Livia S. Boyadjian

NAME

Reg. No. 34,781

REGISTRATION NUMBER

Certificate of Mailing By Express Mailing under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 in an envelope addressed to:

Assistant Commissioner for Patents
Washington, D.C. 20231

on March 13, 2002.
Date


Signature

Randolph McQueen

Typed or printed name of person signing Certificate

EL 825522628 US

("Express Mail" Mailing Label Number)

Note: Each paper must have its own certificate of mailing by Express Mail, or this certificate must identify each submitted paper.

Re.: Docket No.: 800.1015
Applicant(s): Alexander KOZAK, et al.
Invention: PHOSPHOLIPID PRODRUGS OF ANTI-PROLIFERATIVE DRUGS
Filing Date: Herewith

Transmittal Letter to the United States Designated/Elected Office (DO/EO /US) (2 pages);
Copy of International Application (51 pages);
Copy of the PCT International Search Report (4 pages);
Copy of PCT Request (5 pages);
Copy of Notification of Receipt of Demand (Form PCT/IPEA/402) (1 page);
Information Disclosure Statement (2 pages); Form PTO 1449 (1 page); Copies of References Cited (11 References)
Preliminary Amendment (5 pages);
Declaration/Power of Attorney (4 pages);
Recordation Form Cover Sheet (1 page); Executed Assignment (4 pages);
Letter re Priority (1 page);
Checks in the amount of \$436.00 and \$40.00.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re: Application of: Alexander KOZAK, et al.
Serial No.: To Be Assigned
Filed: Herewith
For: **PHOSPHOLIPID PRODRUGS OF ANTI-
PROLIFERATIVE DRUGS**

Assistant Commissioner for Patents
Washington, D.C. 20231

March 13, 2002

LETTER RE: PRIORITY

Sir:

Applicants hereby claim priority from Israeli Patent Application No. 131887 filed September 14, 1999 through International Application Serial No. PCT/IL00/00562 filed September 13, 2000.

Respectfully submitted,

DAVIDSON, DAVIDSON & KAPPEL, LLC

By: 

Livia S. Boyadjian
Reg. No. 34,781

DAVIDSON, DAVIDSON & KAPPEL, LLC
485 Seventh Avenue, 14th Floor
New York, NY 10018
(212) 736-1940

"Express Mail" mailing label no. EL 825522628 US

Date of Deposit: March 13, 2002

I hereby certify that this correspondence and/or documents referred to as attached therein and/or fee are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above, in an envelope addressed to "Assistant Commissioner for Patents, Washington, D.C. 20231".

DAVIDSON, DAVIDSON & KAPPEL, LLC

By: 